Sonnet BioTherapeutics Highlights Safety Profile For Lead Cancer Candidate

Sonnet BioTherapeutics Holdings Inc SONN says that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 trials.
The adverse events have generally been mild/moderate, transient in nature, and have all been tolerable. In addition, they have been less numerous and less intense with subsequent doses.
There was minimal/no signal for IL-1β, IL-6, IL-8, or TNFα and no indication of cytokine release syndrome (CRS). IL-10 was also induced at a low level, as expected.
Related: Sonnet BioTherapeutics Shares Jump After Janssen Pact For Its Three Product Candidates.
Five of the six patients had stable disease at the first follow-up scan, with one patient progressing who is now off study. Investors are may be reacting to this.
As of the most recent scan, 2 of the five stable disease patients remain stable, while the others had tumor growth that may represent tumor inflammation or unconfirmed progression.
One endometrial stromal sarcoma patient progressing at study entry has evidence of improvement after six months on SON-1010 with smaller tumors and complete resolution of ascites.
Price Action: SONN shares are down 27.40% at $2.06 on the last check Wednesday.